Edition:
United Kingdom

BeiGene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

93.60USD
15 Dec 2017
Change (% chg)

$-0.27 (-0.29%)
Prev Close
$93.87
Open
$94.64
Day's High
$94.93
Day's Low
$92.20
Volume
270,604
Avg. Vol
123,214
52-wk High
$118.71
52-wk Low
$27.94

Latest Key Developments (Source: Significant Developments)

Beigene Ltd qtrly ‍net income attributable to common shareholders per ADS, diluted $2.54​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Beigene Ltd ::Beigene reports third quarter 2017 financial results.Beigene Ltd - qtrly ‍net income attributable to common shareholders per ads, diluted $2.54​.  Full Article

Beigene receives approval to initiate clinical trials in China
Thursday, 18 Aug 2016 

Beigene Ltd : Beigene receives approval to initiate clinical trials in china with parp inhibitor BGB-290 .Received clinical trial application approval from China Food And Drug Administration (CFDA) to conduct clinical trials in China with BGB-290.  Full Article

Beigene Q2 earnings per share view $-0.68, revenue view $1.4 mln -- Thomson Reuters I/B/E/S
Wednesday, 10 Aug 2016 

Beigene Ltd : Beigene reports second quarter 2016 financial results . Qtrly net loss per ads $0.73 . Revenue for three months ended June 30, 2016 was $0.39 million, compared to $1.38 million for three months ended June 30, 2015 .Q2 earnings per share view $-0.68, revenue view $1.4 million -- Thomson Reuters I/B/E/S.  Full Article

Beigene reports Q1 loss per share $0.97
Wednesday, 11 May 2016 

Beigene Ltd : Qtrly loss per share $0.97 . Revenue for the three months ended march 31, 2016 was $0.68 million, compared to $1.38 million for the three months ended march 31, 2015 .Beigene reports first quarter 2016 financial results.  Full Article